New Product Theater: Spikevax Bivalent mRNA COVID-19 Vaccine (Original/Omicron BA.4-5)

Medical Affairs Post-Event Survey

We are trying to improve the event experience continually and to provide you with the most relevant information at the right time. We would love to hear about your event experience and appreciate your thoughtful responses. Privacy Policy

Q2 How likely are you to recommend this event to a colleague? *

Extremely likely (5)	Very likely (4)	Somewhat likely (3)	Not very likely (2)	Not at all likely (1)
Extremely likely (5)Item #1 Extremely likely (5)	Very likely (4)Item #1 Very likely (4)	Somewhat likely (3)Item #1 Somewhat likely (3)	Not very likely (2)Item #1 Not very likely (2)	Not at all likely (1)Item #1 Not at all likely (1)

Q3 The content met the learning objectives of the program. *

Strongly agree (5)	Agree (4)	Neither agree nor disagree (3)	Disagree (2)	Strongly disagree (1)
Strongly agree (5)Item #1 Strongly agree (5)	Agree (4)Item #1 Agree (4)	Neither agree nor disagree (3)Item #1 Neither agree nor disagree (3)	Disagree (2)Item #1 Disagree (2)	Strongly disagree (1)Item #1 Strongly disagree (1)

Q4 Please rate the speaker's knowledge of the topic. *

Excellent (5)	Good (4)	Average (3)	Fair (2)	Poor (1)
Excellent (5)Item #1 Excellent (5)	Good (4)Item #1 Good (4)	Average (3)Item #1 Average (3)	Fair (2)Item #1 Fair (2)	Poor (1)Item #1 Poor (1)

Q5 The content was clearly communicated by the speaker and easy to understand. *

Strongly agree (5)	Agree (4)	Neither agree nor disagree (3)	Disagree (2)	Strongly disagree (1)
Strongly agree (5)Item #1 Strongly agree (5)	Agree (4)Item #1 Agree (4)	Neither agree nor disagree (3)Item #1 Neither agree nor disagree (3)	Disagree (2)Item #1 Disagree (2)	Strongly disagree (1)Item #1 Strongly disagree (1)

Q6 How would you rate the session in terms of increasing your knowledge on the following topics? Please answer the questions above using a scale where:

Q6 How would you rate the session in terms of increasing your knowledge on the following topics? *

	Excellent (5)	Good (4)	Average (3)	Fair (2)	Poor (1)
Clinical development and data	Excellent (5)Clinical development and data Excellent (5)	Good (4)Clinical development and data Good (4)	Average (3)Clinical development and data Average (3)	Fair (2)Clinical development and data Fair (2)	Poor (1)Clinical development and data Poor (1)
Indications and dosing schedule	Excellent (5)Indications and dosing schedule Excellent (5)	Good (4)Indications and dosing schedule Good (4)	Average (3)Indications and dosing schedule Average (3)	Fair (2)Indications and dosing schedule Fair (2)	Poor (1)Indications and dosing schedule Poor (1)
Preparation before injection, form, and storage	Excellent (5)Preparation before injection, form, and storage Excellent (5)	Good (4)Preparation before injection, form, and storage Good (4)	Average (3)Preparation before injection, form, and storage Average (3)	Fair (2)Preparation before injection, form, and storage Fair (2)	Poor (1)Preparation before injection, form, and storage Poor (1)
Co-administration	Excellent (5)Co-administration Excellent (5)	Good (4)Co-administration Good (4)	Average (3)Co-administration Average (3)	Fair (2)Co-administration Fair (2)	Poor (1)Co-administration Poor (1)
Precautions for use and contraindications	Excellent (5)Precautions for use and contraindications Excellent (5)	Good (4)Precautions for use and contraindications Good (4)	Average (3)Precautions for use and contraindications Average (3)	Fair (2)Precautions for use and contraindications Fair (2)	Poor (1)Precautions for use and contraindications Poor (1)
Safety	Excellent (5)Safety Excellent (5)	Good (4)Safety Good (4)	Average (3)Safety Average (3)	Fair (2)Safety Fair (2)	Poor (1)Safety Poor (1)
Recommendations	Excellent (5)Recommendations Excellent (5)	Good (4)Recommendations Good (4)	Average (3)Recommendations Average (3)	Fair (2)Recommendations Fair (2)	Poor (1)Recommendations Poor (1)

Q7 How likely are you to apply the knowledge learned into your practice? *

Extremely likely (5)	Very likely (4)	Somewhat likely (3)	Not very likely (2)	Not at all likely (1)
Extremely likely (5)Item #1 Extremely likely (5)	Very likely (4)Item #1 Very likely (4)	Somewhat likely (3)Item #1 Somewhat likely (3)	Not very likely (2)Item #1 Not very likely (2)	Not at all likely (1)Item #1 Not at all likely (1)

Q8 I would like to hear more from this speaker. *

Strongly agree (5)	Agree (4)	Neither agree nor disagree (3)	Disagree (2)	Strongly disagree (1)
Strongly agree (5)Item #1 Strongly agree (5)	Agree (4)Item #1 Agree (4)	Neither agree nor disagree (3)Item #1 Neither agree nor disagree (3)	Disagree (2)Item #1 Disagree (2)	Strongly disagree (1)Item #1 Strongly disagree (1)

MED-HK-mRNA1273.222-2300007 l August 2023